We estimate that about 70,000 adults with DS in the United States are at risk for DS‐AD, which shares with AD clinical features and neuropathological hallmarks, including Aβ plaques and neurofibrillary tangles,5 but with differences in age‐dependent changes in the levels of Aβ and tau prion‐like species.6 The gene discussed is MAPT; the disease is Dravet syndrome.